References
- Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction, 99, 425–430.
- Roos JL, Pretorius, Karayiorgou M, Boraine Cannabis and other variables affecting age at onset in a schizophrenia founder population. S. Afr Psychiatry Review. 2006, 9: 99–103.
- Parry CD, Myers B, Morojele NK, Flisher AJ, Bhana A, Donson, Pludderman A. Trends in adolescent alcohol and other drug use: Findings from three sentinel sites in South Africa. J. Adolesc. 2001, 27(4) 429–440.
- Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry. 2000, 22: 224–35.
- Cohn TA. Metabolic Effects of Antipsychotic Treatment: Between a rock and a hard place? Can J Psychiatry, Vol 51, No 8, July 2006.
- Faulkner G, Cohn TA. Pharmacological and nonpharmacological strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry, Vol 51, No 8, July 2006.
- Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006, 354 1445–1447.
- Shader RI, Oesterheld JR. Facts and public policy: should I keep my child on ADHD Drugs. Journal of Clinical Psychopharmacology. Vol 26, No 3, June 2006, 223.